Timothy D. Hunt

Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA.

GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.

BGR Holding LLC provides legal services. It employs lawyers, policy specialists and other professionals to represents the interests of its clients at the federal level. BGR clients include international governments, trade associations, non-profits, academic institutions, hospitals, coalitions, state and local governments. The company was founded by Haley R. Barbourm, Lanny Griffith and Edward M. Rogers in 1991 and is headquartered in Washington, DC.

The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.